Insulin pump risks and benefits: A clinical appraisal of pump safety standards, adverse event reporting, and research needs

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 716-722

  Heinemann, Lutz ^a   Fleming, G Alexander ^b   Petrie, John R ^c   Holl, Reinhard W ^d   Bergenstal, Richard M ^e   Peters, Anne L ^f  

^a Science and Co   (Germany)

^b Kinexum   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF ULM   (Germany)

^e INTERNATIONAL DIABETES CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN GLULISINE;

ARTICLE; CLINICAL EFFECTIVENESS; CONSUMER HEALTH INFORMATION; DEVICE APPROVAL; DEVICE SAFETY; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MEDICATION COMPLIANCE; PATIENT EDUCATION; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; ADVERSE EFFECTS; DEVICE FAILURE; DEVICE RECALL; DIABETES MELLITUS, TYPE 1; DRUG SURVEILLANCE PROGRAM; EUROPE; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN INFUSION; RISK ASSESSMENT; STANDARDS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DEVICE APPROVAL; DIABETES MELLITUS, TYPE 1; EQUIPMENT FAILURE; EUROPE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN; INSULIN INFUSION SYSTEMS; MEDICAL DEVICE RECALLS; RISK ASSESSMENT; UNITED STATES;

EID: 84939808599     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0168     Document Type: Article

References (30)

1. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: An approach to achieving normoglycaemia. BMJ 1978;1:204-207.
2. Pickup J. Insulin pumps. Diabetes Technol Ther 2013;15(Suppl. 1):S24-S28.
3. Ly TT, Nicholas JA, Retterath A, LimEM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: A randomized clinical trial. JAMA 2013;310: 1240-1247.
4. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Thresholdbased insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369:224-232.
5. Grunberger G, Abelseth JM, Bailey TS, et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin PumpManagement Task Force. Endocr Pract 2014;20:463-489.
6. Diabetes UK. Insulin pumptherapy. Also known as continuous subcutaneous insulin infusion (CSII). Position statement (updated September 2011). Available from www.diabetes.org.uk/Documents/Position%20statements/Position-Statment-Insulin-pump-therapy090911.pdf. Accessed 24 December 2014.
7. Maahs DM, Horton LA, Chase HP. The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther 2010;12(Suppl. 1):S59-S65.
8. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012;97:4383-4389.
9. Close Concerns.Medtronic issues class II recall for MiniMed Paradigm and 530G systems [Internet], 2014. Available from www.closeconcerns.com/knowledgebase/r/846b6e3d. Accessed 24 December 2014.
10. US Food and Drug Administration. Infusion pumps total product life cycle. Guidance for industry and FDA staff [Internet], 2014. Available from www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM209337.pdf. Accessed 22 January 2015.
11. US Food and Drug Administration. Draft guidance for industry and Food andDrug Administration staff - medical device reporting for manufacturers [Internet], 2013. Available from www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm359130.htm. Accessed 25 October 2014.
12. US Food and Drug Administration. Deciding when to submit a 510(k) for a change to an existing device (K97-1) [Internet], 1997. Available from www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080235.htm. Accessed 25 October 2014.
13. Council of the European Union. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices [Internet], 1993. Available from http://eur-lex.europa.eu/legal-content/en/ALL/;ELX-SESSIONID5YJQGJLGd1JrpT98QbJKC8KMcchrTtQfzj1fjznyTjVv1p2vfp6bh!283099387?uri5CELEX:31993L0042. Accessed 25 October 2014.
14. Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the United States and European Union. N Engl J Med 2012;366:848-855.
15. European Commission DG Health and Consumers (SANCO). Guidelines on aMedical Devices Vigilance System [Internet], 2013. Available from http://ec.europa.eu/health/medical-devices/files/meddev/2-12-1-ol-en.pdf Accessed 11 November 2014.
16. Cope JU, Morrison AE, Samuels-Reid J. Adolescent use of insulin and patient-controlled analgesia pump technology: A 10-year Food and Drug Administration retrospective study of adverse events. Pediatrics 2008;121: e1133-e1138.
17. Regittnig W, Urschitz M, Lehki B, et al. Absorption kinetics of insulin following subcutaneous bolus administration with different bolus durations. Diabetes 2013;62(Suppl. 1):A247.
18. Heinemann L. Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements? J Diabetes Sci Tech 2009;3:1490-1500.
19. US Food and Drug Administration. Human factors and medical devices [Internet], 2014. Available from www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HumanFactors/. Accessed 25 October 2014.
20. Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2013;39:445-453.
21. Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Tech 2012;6:954-964.
22. Mecklenburg RS, Guinn TS, Sannar CA, Blumenstein BA. Malfunction of continuous subcutaneous insulin infusion systems: A oneyear prospective study of 127 patients. Diabetes Care 1986;9:351-355.
23. Campbell MS, Schatz DA, Chen V, et al.; T1D Exchange Clinic Network. A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience. Pediatr Diabetes 2014;15: 110-117.
24. Simmons JH, Chen V, Miller KM, et al.; T1D Exchange Clinic Network. Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry. Diabetes Care 2013; 36:3573-3577.
25. Lee JM. Glu together as one: An innovative online social network for engaging patients with type 1 diabetes and their caregivers and advancing research to improve the lives of patients with type 1 diabetes [Internet], 2012. Available from http://medicinex.stanford.edu/jleeabstract/Accessed 25 October 2014.
26. Gudbjornsdottir S, Eliasson B, Svensson AM, et al. Insulin pumps (CSII) and cardiovascular diseases and mortality in the Swedish national diabetes register. Diabetologia 2014; 57(Suppl.1):A196.
27. Guilhem I, Leguerrier AM, Lecordier F, Poirier JY, Maugendre D. Technical risks with subcutaneous insulin infusion. Diabetes Metab 2006;32:279-284.
28. Guilhem I, Balkau B, Lecordier F, et al. Insulin pump failures are still frequent: A prospective study over 6 years from 2001 to 2007. Diabetologia 2009;52:2662-2664.
29. de Vries L, Grushka Y, Lebenthal Y, Shalitin S, Phillip M. Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes. Pediatr Diabetes 2011;12:506-512.
30. Hofer SE, Heidtmann B, Raile K, et al.; DPVScience- Initiative and the German working group for insulin pump treatment in pediatric patients. Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria. Pediatr Diabetes 2010;11:116-121.